Effect of matrine on tumor growth and inflammatory factors and immune function in Wistar rat with breast cancer.
10.12047/j.cjap.5657.2018.086
- Author:
Rui-Kui ZHANG
1
;
Chao WANG
1
Author Information
1. Department of Surgical Oncology, Affiliated Hospital of Logistics College of Chinese People's Armed Police Force, Tianjin 300162, China.
- Publication Type:Journal Article
- Keywords:
immune function;
inflammatory factor;
matrine, breast cancer cell tumor-bearing;
rats
- MeSH:
Alkaloids;
Animals;
Breast Neoplasms;
Female;
Quinolizines;
Rats;
Rats, Wistar
- From:
Chinese Journal of Applied Physiology
2018;34(4):375-378
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effect of matrine on tumor growth, inflammatory factors and immune function in Wistar rat with breast cancer.
METHODS:Sixty female Wistar rats were randomly divided into control group (=10) and the modeling group of breast cancer cell tumor-bearing rat (=50), then the rats in modeling group were randomly divided into five groups (=10):vehicle group, matrine low dose group (50 mg/kg), medium dose group (100 mg/kg), high dose group (200 mg/kg), and lentinan group (200 mg/kg). Except the control group, each rat in the other groups was subcutaneously inoculated 0.4 ml Walker 256 breast cancer cell suspension (5×10 cells/ml) in the right axillary. Each group was treated with corresponding drug by ig administration (10 ml/kg body weight) twice a day for 14 days. After 14 days, the blood sample was collected from ventral aorta, the tumor was removed and weighed to calculate tumor inhibitory rate. The levels of interleukin-2 (IL-2), interferon-γ (IFN-γ), interleukin-6 (IL-6), interleukin-10 (IL-10), transforming growth factor-β (TGF-β), CD3, CD4, CD8, IgG, IgM, IgA in peripheral blood were determined.
RESULTS:The mean tumor weight of matrine low-dose, medium-dose, high-dose groups and lentinan group were (4.99±0.93) g, (4.52±0.92) g, (4.22±1.18) g and (4.52±0.92) g respectively, which were significantly lower than that in model group. There was no statistical difference on the mean tumor weight among matrine groups and lentinan group (>0.05). After the drug intervention, the tumor inhibitory rates of matrine low-dose, medium dose, high-dose groups and lentinan group were 24.6%, 31.7%, 36.3%, and 27.9% respectively, there was no statistical difference among the four groups. The levels of IL-2, IFN-γ, CD8+ in vehicle group were lower than those of control group obviously (<0.01), however, the levels of IL-6, IL-10, TGF-β, CD3, CD4, IgG, IgM, IgA were higher significantly than those of control group (<0.01). The levels of IL-2, IFN-γ, CD8 in matrine low-dose, medium dose, high-dose groups and lentinan group were higher than those of vehicle group obviously (<0.01, <0.05); while the levels of IL-6, IL-10, TGF-β, CD3, CD4, IgG, IgM, IgA were lower than those of model group markedly (<0.01, <0.05). The levels of IgM and IgA in matrine low-dose and medium-dose groups were higher than those of lentinan group obviously (<0.01, <0.05); the levels of IL-2, IFN-γ and IgA in matrine high-dose group were higher than those of lentinan group obviously (<0.01, <0.05); while the levels of IFN-γ in matrine low-dose group were lower than those of lentinan group markedly (<0.05); the levels of IL-10 and CD4 in matrine high-dose group were lower than those of lentinan group markedly (<0.01, <0.05).
CONCLUSIONS:Matrine has an obvious antitumor action which is related to its ability to enhance cellular and humoral immunity, reduce inflammatory reaction.
